Advertisement

Systemic Sclerosis (Scleroderma) and Raynaud’s Phenomenon

  • Janet E. Pope
  • Philip J. Clements
  • Daniel E. Furst
  • Laura K. Hummers
  • Dinesh Khanna
  • Maureen D. Mayes
  • Thomas Medsger
  • James Seibold
  • Virginia Steen

Abstract

Systemic sclerosis (scleroderma; SSc) is a chronic con nective tissue disease characterized by inflammation within, and fibrosis of, the skin, vascular abnormalities, visceral damage, and the production of autoantibodies. SSc is divided generally into limited and diffuse forms, based on the extent of skin involvement. A group of conditions known as “localized” sclero-derma, which includes morphea, linear scleroderma, and en coup de sabre, is discussed in the chapter on Scleroderma Mimickers (Chap. 11). Diffuse SSc has a greater extent of skin involvement and is more likely to be associated with renal crisis, pulmonary fibrosis, and cardiomyopathy. Patients with diffuse SSc have a higher mortality rate. Pulmonary disease remains a major source of morbidity and mortality for patients with SSc. Patients with limited SSc are predisposed to the development of pulmonary arterial hypertension (PAH). Those with diffuse SSc are predisposed to interstitial fibrosis. Autoantibody profiles can predict to a certain extent the types of organ involvement that can be expected in SSc. Raynaud's phenomenon (RP) is characterized by vasospasm of the digital arteries that leads to well-demarcated pallor with cyanosis and rubor. RP is essentially universal among patients with SSc and is the first symptom in a large majority of patients. Primary RP is often mild enough not to require treatment; however, with secondary RP from SSc, there is not only vasospasm but also fixed blood vessel problems with luminal narrowing, so the ischemia can be more severe. Complications of RP in SSc can include digital ulcers often leading to infection and amputation causing pain and functional disability. Diffuse SSc often presents with puffiness of the hands associated with pain, in a way that can mimic rheumatoid arthritis. RP often occurs around the time of development of puffy hands in diffuse SSc.

Keywords

Pulmonary Arterial Hypertension Primary Biliary Cirrhosis Interstitial Lung Disease Forced Vital Capacity Health Assessment Questionnaire Disability Index 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Al-Dhaher FF, Pope JE, Ouimet JM. Determinants of morbidity and mortality of systemic sclerosis in Canada. Semin Arthritis Rheum. 2009 (in press)Google Scholar
  2. American Thoracic Society Statement. Guidelines for the six-minute walk test. Am J Respir Care Med. 2002;166:111–7Google Scholar
  3. Arcasoy SM. Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. Am J Respir Crit Care Med. 2003;167:735–40PubMedCrossRefGoogle Scholar
  4. Arnett FC, Cho M, Chatterjee S, et al Familial occurrence frequencies and relative risks for systemic sclerosis (scleroderma) in three United States cohorts. Arthritis Rheum. 2001;44: 1359–62PubMedCrossRefGoogle Scholar
  5. Behr J, Vogelmeier C, Beinert T, et al Bronchoalveolar lavage for evaluation and management of scleroderma disease of the lung. Am J Respir Crit Care Med. 1996;154:400–6PubMedCrossRefGoogle Scholar
  6. Calamia KT, Scolapio JS, Viggiano TR. Endoscopic YAG laser treatment of watermelon stomach (gastric antral vascular ectasia) in patients with systemic sclerosis. Clin Exp Rheumatol. 2000; 18(5):605–8PubMedGoogle Scholar
  7. Claman HN, Giorno RC, Seibold JR. Endothelial and fibroblastic activation in scleroderma. The myth of the “uninvolved skin”. Arthritis Rheum. 1991;34:1495–501PubMedCrossRefGoogle Scholar
  8. Clements P, Lauchenbruch P, Furst D, Paulus H. The course of skin involvement in systemic sclerosis over three years in a trial of chlorambucil versus placebo. Arthritis Rheum. 1993;36:1575–9PubMedCrossRefGoogle Scholar
  9. Clements PJ, Medsger TA Jr, Feghali CA. Cutaneous involvement in systemic sclerosis. In: Clements PJ, Furst DE, editors. Chapter 7 Systemic sclerosis. 2nd ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2004. p. 129–50Google Scholar
  10. Cutolo M, Pizzorni C, Tuccio M, et al Nailfold videocapillaroscopic patterns and serum autoantibodies in systemic sclerosis. Rheumatology (Oxford) 2004;43(6):719–26CrossRefGoogle Scholar
  11. De Oliviera NC, dos Santos Sabbag LM, et al Reduced exercise capacity in systemic sclerosis patients without pulmonary involvement. Scand J Rheumatol. 2007;36:458–61CrossRefGoogle Scholar
  12. Ebert EC. Esophageal disease in scleroderma. J Clin Gastroenterol. 2006;40:769–75PubMedCrossRefGoogle Scholar
  13. Furst DE, Saab M, Clements P. Clinical and serological comparison of 17 PSS and 17 CREST syndrome patients for sex, age and matched disease duration. Ann Rheum Dis. 1984;43:794–801PubMedCrossRefGoogle Scholar
  14. Goh NS, Veeraraghavan S, Desai SR, et al Bronchoalveolar lavage cellular profiles in patients with systemic sclerosis-associated interstitial lung disease are not predictive of disease progression. Arthritis Rheum. 2007;56:2005–12PubMedCrossRefGoogle Scholar
  15. Herrick A. Pathogenesis of Raynaud's phenomenon. Rheumatology (Oxford) 2005;44(5):587–96CrossRefGoogle Scholar
  16. Hirschl M, Hirschl K, Lenz, et al Transition from primary Raynaud's phenomenon to secondary Raynaud's phenomenon identified by diagnosis of an associated disease results of ten years of prospective surveillance. Arthritis Rheum. 2006;54(6):1974–81PubMedCrossRefGoogle Scholar
  17. Hoyles RK, Ellis RW, Wellsbury J, et al A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum. 2006;54(12):3962–70PubMedCrossRefGoogle Scholar
  18. Hudson M, Thombs BD, Panopalis P, et al Quality of life in patients with systemic sclerosis compared to the general population and patients with other chronic conditions. J Rheumatol 2009;36:768–72PubMedCrossRefGoogle Scholar
  19. Khanna D. Health-related quality of life: A primer with a focus on scle-roderma. Scleroderma Care Res. 2006;3(2):3–13Google Scholar
  20. Khanna D, Furst DE, Clements PJ, et al Oral cyclophosphamide for active scleroderma lung disease: a decision analysis. Med Decis Making. 2008;28(6):926–37PubMedCrossRefGoogle Scholar
  21. Kuwana M, Kaburaki J, Okano Y, et al Clinical and prognostic associations based on serum antinuclear antibodies in Japanese patients with systemic sclerosis. Arthritis Rheum. 1994;37(1):75–83PubMedCrossRefGoogle Scholar
  22. Kuwana M, Feghali CA, Medsger TA Jr, Wright TM. Autoreactive T cells to topoisomerase I in monozygotic twins discordant for systemic sclerosis. Arthritis Rheum. 2001;44:1654–59PubMedCrossRefGoogle Scholar
  23. Lock G, Holstege A, Lang B, Scholmerich J. Gastrointestinal manifestations of progressive systemic sclerosis. Am J Gastroenterol. 1997;92(5):763–71PubMedGoogle Scholar
  24. Lori S, Matucci-Cerinic M, Casale R, et al Peripheral nervous system involvement in systemic sclerosis: The median nerve as target structure. Clin Exp Rheumatol. 1996;14(6):601–05PubMedGoogle Scholar
  25. Luggen M, Belhorn L, Evans T, Fitzgerald O, Spencer-Green G. The evolution of Raynaud's phenomenon: A longterm prospective study. J Rheumatol. 1995;22(12):2226–32PubMedGoogle Scholar
  26. Lynch JP 3rd, Saggar R, Weigt SS, et al Usual interstitial pneumonia. Semin Respir Crit Care Med. 2006;27(6):634–51PubMedCrossRefGoogle Scholar
  27. Marie I. Gatrointestinal involvement in systemic sclerosis. Presse Med. 1996;35:1952–65CrossRefGoogle Scholar
  28. Marie I, Dominique S, Levesque H, et al Esophageal involvement and pulmonary manifestations in systemic sclerosis. Arthritis Rheum. 2001;45(4):346–54PubMedCrossRefGoogle Scholar
  29. Mathai SC, Hummers LK, Champion HC, et al Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: Impact of interstitial lung disease. Arthritis Rheum. 2009;60(2): 569–77PubMedCrossRefGoogle Scholar
  30. Medsger TA Jr. Unpublished data from the University of Pittsburgh Scleroderma Databank, 2009Google Scholar
  31. Meli M, Gitzelmann G, Koppensteiner R, et al Predictive value of nail-fold capillaroscopy in patients with Raynaud's phenomenon. Clin Rheumatol. 2006;25(2):153–8PubMedCrossRefGoogle Scholar
  32. Merkel PA, Herlyn K, Martin RW, et al Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon. Arthritis Rheum. 2002;46(9):2410–20PubMedCrossRefGoogle Scholar
  33. Morelli S, Ferrante L, Sgreccia A, et al Pulmonary hypertension is associated with impaired exercise capacity in patients with systemic sclerosis. Scand J Rheumatol. 2000;29:236–42PubMedCrossRefGoogle Scholar
  34. No authors: American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med. 2000;161:646–64Google Scholar
  35. Pavlov-Dolijanovic S, Damjanov N, Ostojic P, et al The prognostic value of nailfold capillary changes for the development of connective tissue disease in children and adolescents with primary Raynaud's phenomenon: A follow-up study of 250 patients. Pediatr Dermatol. 2006;23(5):437–42PubMedCrossRefGoogle Scholar
  36. Penn H, Howie AJ, Kingdon EJ, Bunn CC, Stratton RJ, Black CM, et al Scleroderma renal crisis: Patient characteristics and long-term outcomes. QJM 2007;100(8):485–94PubMedCrossRefGoogle Scholar
  37. Perera A, Fertig N, Lucas M, et al Clinical subsets, skin thickness progression rate, and serum antibody levels in systemic sclerosis patients with anti-topoisomerase I antibody. Arthritis Rheum. 2007; 56:2740–6PubMedCrossRefGoogle Scholar
  38. Plastiras SC, Karadimitrakis SP, Ziakas PD, et al Scleroderma lung: Initial forced vital capacity as predictor of pulmonary function decline. Arthritis Rheum. 2006;55(4):598–602PubMedCrossRefGoogle Scholar
  39. Poole JL, Williams CA, Bloch DA, et al Concurrent validity of the Health Assessment Questionnaire disability index in scleroderma. Arthritis Care Res. 1995;8:189–93PubMedCrossRefGoogle Scholar
  40. Pope J. Scleroderma Overlap Syndromes. Curr Opin Rheumatol. 2002; 14(6):704–10PubMedCrossRefGoogle Scholar
  41. Pope J. The diagnosis and treatment of Raynaud's phenomenon: A practical approach. Drugs 2007;67(4):517–25PubMedCrossRefGoogle Scholar
  42. Pope J. Raynaud's phenomenon (primary). Clin Evidence. 2003a;9: 1339–48Google Scholar
  43. Pope J, Lee P, Baron M, Dunne J, Smith D, Docherty PS. The prevalence of elevated pulmonary arterial pressures as measured by echocardiography in a large multi-centre cohort of systemic sclerosis subjects in Canada. J Rheumatol. 2005a;32(7):1273–8Google Scholar
  44. Pope JE. Musculoskeletal involvement in scleroderma. Rheum Dis Clin North Am Scleroderma 2003b May 29:391–408CrossRefGoogle Scholar
  45. Pope JE. Other manifestations of mixed connective tissue disease. Rheum Dis Clin North Am. 2005b;31(3):519–33CrossRefGoogle Scholar
  46. Pope JE, Thompson A. Antimitochondrial antibodies and their signifi-cance in diffuse and limited scleroderma. J Clin Rheumatol. 1999; 5(4):206–9PubMedCrossRefGoogle Scholar
  47. Pope JE, Shum D, Gottschalk R, et al Increased pigmentation in sclero-derma. J Rheumatol. 1996;23:1912–16PubMedGoogle Scholar
  48. Pope JE, Al-Bishri J, Al-Azem H, Ouimet JM. The temporal relationship of Raynaud's phenomenon and features of connective tissue disease in rheumatoid arthritis. J Rheumatol. 2008;35(12):2329–33PubMedCrossRefGoogle Scholar
  49. Rhew EY, Barr, WG. Scleroderma renal crisis: new insights and developments. Curr Rheumatol. Rep 2004;6(2):129–36PubMedCrossRefGoogle Scholar
  50. Rigamonti C, Shand LM, Feudjo M, et al Clinical features and prognosis of primary biliary cirrhosis associated with systemic sclerosis. Gut 2006;55(3):388–94PubMedCrossRefGoogle Scholar
  51. Sacks DG, Okano Y, Steen VD, et al Isolated pulmonary hypertension in systemic sclerosis with diffuse cutaneous involvement: Association with serum anti-U3RNP antibody. J Rheumatol. 1996; 23(4):639–42PubMedGoogle Scholar
  52. Salliot C, Mouthon L, Ardizzone M, et al Sjögren's syndrome is associated with and not secondary to systemic sclerosis. Rheumatology (Oxford) 2007;46(2):321–6CrossRefGoogle Scholar
  53. Shand L, Lung M, Nihtyanova S, et al Relationship between change in skin score and disease outcome in diffuse cutaneous systemic sclerosis. Application of a latent linear trajectory model. Arthritis Rheum. 2007;56(7):2422–31PubMedCrossRefGoogle Scholar
  54. Shibukawa G, Irisawa A, Sakamoto N, et al Gastric antral vascular ecta-sia (GAVE) associated with systemic sclerosis: Relapse after endo-scopic treatment by argon plasma coagulation. Intern Med. 2007;46 (6):279–83PubMedCrossRefGoogle Scholar
  55. Silver RM, Miller KS, Kinsella, et al Evaluation and management of scleroderma lung disease using bronchoalveolar lavage. Am J Med. 1990;88:470–6PubMedCrossRefGoogle Scholar
  56. Steen V. Epidemiology of systemic sclerosis. In: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH, editors. Rheumatology. Vol. 2. Toronto: Elsevier(Mosby); 2003. p. 1455–61Google Scholar
  57. Steen V. Advancements in diagnosis of pulmonary arterial hypertension in scleroderma. Arthritis Rheum. 2005a;52(12):3698–700CrossRefGoogle Scholar
  58. Steen V, Medsger T. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum. 2000;43(11):2437–44PubMedCrossRefGoogle Scholar
  59. Steen VD. Scleroderma renal crisis. Rheum Dis Clin North Am. 2003;29(2):315–33PubMedCrossRefGoogle Scholar
  60. Steen VD. Autoantibodies in systemic sclerosis. Semin Arthritis Rheum. 2005b;35(1):35–42CrossRefGoogle Scholar
  61. Steen VD, Medsger TA Jr. The palpable tendon friction rub: An important physical examination finding in patients with systemic sclerosis. Arthritis Rheum. 1997a;40:1146–51CrossRefGoogle Scholar
  62. Steen VD, Medsger TA Jr. The value of the Health Assessment Questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time. Arthritis Rheum. 1997b;40:1984–91CrossRefGoogle Scholar
  63. Steen VD, Medsger TA Jr. Long-term outcomes of scleroderma renal crisis. Ann Intern Med. 2000;133(8):600–3PubMedCrossRefGoogle Scholar
  64. Steen VD, Ziegler GL, Rodnan GP, Medsger TA Jr. Clinical and laboratory associations of anticentromere antibody in patients with progressive systemic sclerosis. Arthritis Rheum. 1984;27(2):125–31PubMedCrossRefGoogle Scholar
  65. Steen VD, Conte C, Owens GR, Medsger TA Jr. Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum. 1994;37(9): 1283–9PubMedCrossRefGoogle Scholar
  66. Steen VD, Lucas M, Fertig N, Medsger TA Jr. Pulmonary arterial hypertension and severe pulmonary fibrosis in systemic sclerosis patients with a nucleolar antibody. J Rheumatol. 2007;34(11):2230–5PubMedGoogle Scholar
  67. Strange C, Bolster MB, Roth MD, et al Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease. Am J Respir Crit Care Med. 2008;177:91–8PubMedCrossRefGoogle Scholar
  68. Tashkin DP, Elashoff R, Clements PJ, et al Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006;354(25): 2655–66PubMedCrossRefGoogle Scholar
  69. Tashkin DP, Elashoff R, Clements PJ, et al Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in sclero-derma lung disease. Am J Respir Crit Care Med. 2007;176(10): 1026–34PubMedCrossRefGoogle Scholar
  70. Teixeira L, Mahr A, Berezne A, et al Scleroderma renal crisis, still a life-threatening complication. Ann N Y Acad Sci. 2007;1108:249–58PubMedCrossRefGoogle Scholar
  71. Thompson A, Pope JE. A study of the frequency of pericardial and pleural effusions in scleroderma. Br J Rheumatol. 1998;37: 1320–3PubMedCrossRefGoogle Scholar
  72. Thompson AE, Shea B, Welch V, et al Calcium Channel Blockers for Raynaud's Phenomenon in Progressive Systemic Sclerosis. Arthritis Rheum. 2001;44(8):1841–7PubMedCrossRefGoogle Scholar
  73. Walker UA, Tyndall A, Czirjak L, et al Clinical risk assessment of organ manifestations in systemic sclerosis: A report from the EULAR scleroderma trials and research group database. Ann Rheum Dis. 2007;66(6):754–63PubMedCrossRefGoogle Scholar
  74. WGET Research Group. Design of the Wegener's Granulomatosis Etanercept Trial (WGET). Controlled Clinical Trials. 2002;23: 450–68Google Scholar
  75. WGET Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med. 2005;352(4):351–61Google Scholar
  76. White B, Moore WC, Wigley FM, et al Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med. 2000;132:947–54PubMedCrossRefGoogle Scholar
  77. Witt C, Borges AC, John M, et al Pulmonary involvement in diffuse cutaneous systemic sclerosis: Broncheoalveolar fluid granulocyto-sis predicts progression of fibrosing alveolitis. Ann Rheum Dis. 1999;58:635–40PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2009

Authors and Affiliations

  • Janet E. Pope
    • 1
  • Philip J. Clements
    • 2
  • Daniel E. Furst
    • 2
  • Laura K. Hummers
    • 3
  • Dinesh Khanna
    • 2
  • Maureen D. Mayes
    • 4
  • Thomas Medsger
    • 5
  • James Seibold
    • 6
  • Virginia Steen
    • 7
  1. 1.St. Joseph Health CareLondonCanada
  2. 2.UCLA Medical SchoolLos AngelesUSA
  3. 3.Johns Hopkins Scleroderma CenterJohns Hopkins UniversityBaltimoreUSA
  4. 4.University of Texas-Houston Health ScienceHoustonUSA
  5. 5.University of Pittsburgh Medicine/RheumatologyPittsburgh
  6. 6.Division of RheumatologyUniversity of Michigan Medical CenterAnn ArborUSA
  7. 7.Department of RheumatologyGeorgetown University Medical CenterWashingtonUSA

Personalised recommendations